Evinacumab in Patients with Refractory Hypercholesterolemia
- 9 December 2020
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 383 (24), 2307-2319
- https://doi.org/10.1056/NEJMoa2031049
Abstract
BackgroundPatients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum tolerated doses, have an increased risk of atherosclerosis. In such patients, the efficacy and safety of subcutaneous and intravenous evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, are not known. MethodsIn this double-blind, placebo-controlled, phase 2 trial, we enrolled patients with or without heterozygous familial hypercholesterolemia who had refractory hypercholesterolemia, with a screening LDL cholesterol level of 70 mg per deciliter or higher with atherosclerosis or of 100 mg per deciliter or higher without atherosclerosis. Patients were randomly assigned to receive subcutaneous or intravenous evinacumab or placebo. The primary end point was the percent change from baseline in the LDL cholesterol level at week 16 with evinacumab as compared with placebo. ResultsIn total, 272 patients were randomly assigned to the following groups: subcutaneous evinacumab at a dose of 450 mg weekly (40 patients), 300 mg weekly (43 patients), or 300 mg every 2 weeks (39 patients) or placebo (41 patients); or intravenous evinacumab at a dose of 15 mg per kilogram of body weight every 4 weeks (39 patients) or 5 mg per kilogram every 4 weeks (36 patients) or placebo (34 patients). At week 16, the differences in the least-squares mean change from baseline in the LDL cholesterol level between the groups assigned to receive subcutaneous evinacumab at a dose of 450 mg weekly, 300 mg weekly, and 300 mg every 2 weeks and the placebo group were -56.0, -52.9, and -38.5 percentage points, respectively (P<0.001 for all comparisons). The differences between the groups assigned to receive intravenous evinacumab at a dose of 15 mg per kilogram and 5 mg per kilogram and the placebo group were -50.5 percentage points (P<0.001) and -24.2 percentage points, respectively. The incidence of serious adverse events during the treatment period ranged from 3 to 16% across trial groups. ConclusionsIn patients with refractory hypercholesterolemia, the use of evinacumab significantly reduced the LDL cholesterol level, by more than 50% at the maximum dose. (Funded by Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT03175367.) Angiopoietin-like 3 is an inhibitor of lipoprotein lipase. Evinacumab is a monoclonal antibody that inhibits angiopoietin-like 3, activating lipoprotein lipase. In patients with hypercholesterolemia that is refractory to statin and PCSK9 inhibitor therapy, the use of evinacumab reduced plasma lipid levels by more than 50% at the maximum dose.Funding Information
- Regeneron Pharmaceuticals
This publication has 42 references indexed in Scilit:
- 2016 ESC/EAS Guidelines for the Management of DyslipidaemiasAtherosclerosis, 2016
- Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial HypercholesterolemiaJournal of the American Heart Association, 2016
- Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe HypercholesterolemiaJournal of the American College of Cardiology, 2016
- The role of ANGPTL3 in controlling lipoprotein metabolismEndocrine, 2016
- The Agenda for Familial HypercholesterolemiaCirculation, 2015
- ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeysJournal of Lipid Research, 2015
- PCSK9 inhibition to reduce cardiovascular disease riskCurrent Opinion in Endocrinology, Diabetes and Obesity, 2015
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis SocietyEuropean Heart Journal, 2013
- Exome Sequencing,ANGPTL3Mutations, and Familial Combined HypolipidemiaThe New England Journal of Medicine, 2010
- Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative UltracentrifugeClinical Chemistry, 1972